News | May 25, 2023
JB Pharma records revenue growth of 22% to Rs. 762 Cr
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
The company has reported total income of Rs. 1392.72 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
